ISSN 1866-8836
Клеточная терапия и трансплантация

Submission Guidelines for Authors

Please prepare your submission to meet the following standards (this may be used as your checklist before you send us your manuscript):

Title page

  • article title in English;
  • author names with full names, abbreviated middle names and family names of all authors (example: Olga B. Ivanova, William M. P. Smith);
  • working affiliations;
  • a corresponding author address, including postal address, Telephone, Fax and email.

Abstract page

An abstract should be presented in English and in Russian (if possible), recommended length 1500 to 2000 characters. Keywords should be also provided (3 to 8 for each abstract), as well as a short ‘running title’ of fewer than 40 characters.

Article structure

Original articles should contain standard sections, i.e., Introduction, Materials (Patients) and Methods, Results, Discussion/Conclusions, References, and Acknowledgements.

Article length

While an ideal length would be the equivalent of about 10 printed pages typed double-spaced [ca. 5000 words], you may exceed this length if your subject lends itself to it. You might also submit an article shorter than this since some issues are more appropriately dealt with in a concise style. The manuscript should be presented


Any display items should be:

  • accompanied by numbering and captions (providing an additional list of items might be helpful);
  • in 300 dpi quality for the graphs in readable size (there is a complementary print edition of CTT).


Number the tables consecutively with Arabic numerals. Type each separately with titles making them self-explanatory. Define all abbreviations used in each table in a footnote key/legend beneath the table.

Abbreviations and symbols 

Use only standard abbreviations.  Write out all abbreviations in full at first use, with abbreviation following in parentheses, except for standard units of measures (e.g., mg, mL, dL). Avoid using abbreviations in the title of the paper.


  • give the list in plain text, please delete any automatic links to reference managing systems;
  • list your references in alphabetical order (references in non-Latin script systems should come before works written in English);
  • in the article, references should be cited by providing the name of the first authors et al. and the year of publication, if there are only two authors, both should be named; e.g. Friedenstein et al. 1974; Deans and Moseley 2000. Alternatively, you can use the referring numbers of your alphabetical reference list.


If appropriate, please include a section with the title “Acknowledgements” at the end of your article. In your Acknowledgements, please list the following, as applicable:

  • Please give the names of colleagues who have contributed to your work but whose names do not appear among the authors. For contributors please list their full first name, abbreviate the second name and place the family name in the third position. After the name, please state the name and location of the institution in which they work (affiliation) and put this in parentheses. Do not use any titles (no Dr., PhD, etc.).
    Example: “The authors wish to thank Olga P. Ivanova (Hematology Department, University of [town], [country]) for providing the cell line XYZ.”
  • All sources of funding related to the work presented in the manuscript need to be acknowledged in this section. This concerns both institutional and corporate funding.Example: “This work was supported by the Deutsche Forschungsgemeinschaft, grant No. XYZ.”
  • Authors are expected to disclose any potential conflict of interest related to the submitted manuscript, particularly financial conflicts of interest. So, for this purpose, authors should disclose any commercial affiliations or consultancies, stock or equity interests, patent-licensing arrangements, or financial support received by a company which product is related to the study (e.g., a new drug tested described in the manuscript).
    Example: “(Authors) A.I.K. is a consultant of ‘ABC drugs’, P.D.I. has received a personal grant from ‘D.E.F. Pharmaceuticals.”

Additional English language editing

Additional English language editing as well as translation of English abstracts into Russian (for non-native speakers of Russian) is available on acceptance of your submission for publication in CTT.

The articles published in CTT are provided under the following license: Creative Commons Attribution 3.0 Unported,